Search company, investor...
Search
Kyverna Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

kyvernatx.com

Founded Year

2018

Stage

Series B | Alive

Total Raised

$110M

Last Raised

$85M | 8 mos ago

About Kyverna Therapeutics

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress or eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. In addition to developing next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic settings, the company is creating synReg T cells, a synthetic version of Regulatory T cells (Tregs), natural immune cells that control immune homeostasis through multiple immunosuppressive mechanisms.

Kyverna Therapeutics Headquarters Location

5980 Horton St Suite 550

Emeryville, California, 94608,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kyverna Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kyverna Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kyverna Therapeutics Patents

Kyverna Therapeutics has filed 4 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/16/2021

9/20/2022

Transcription factors, Clusters of differentiation, Immunology, Immune system, Molecular biology

Grant

Application Date

12/16/2021

Grant Date

9/20/2022

Title

Related Topics

Transcription factors, Clusters of differentiation, Immunology, Immune system, Molecular biology

Status

Grant

Latest Kyverna Therapeutics News

Kyverna Therapeutics Appoints Tom Van Blarcom as SVP and Head of Research

Aug 26, 2022

Van Blarcom has 15 years of biopharmaceutical industry experience. Tom Van Blarcom. 08.26.22 Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, has appointed Tom Van Blarcom, Ph.D., as senior vice president and head of Research. Van Blarcom has 15 years of biopharmaceutical industry experience leading research teams which have contributed to multiple chimeric antigen receptor (CAR) T cells and bispecific antibodies currently under clinical evaluation. He replaces Kyverna's scientific co-founder Jeffrey Greve, Ph.D., who served as chief scientific officer since the company's inception in 2018. "We are excited to welcome Tom to the Kyverna team. His broad experience in cell therapy research across a wide range of diseases will be invaluable in supporting our work developing engineered T-cell therapies for the treatment of autoimmune diseases," said Dominic Borie, M.D., Ph.D., president and CEO of Kyverna. "Tom's leadership and extensive industry experience will be a critical pillar of our company as we advance our Regulatory T cell (Treg) platform and CAR T programs to achieve our mission of bringing curative living medicines to life to free patients from the siege of autoimmune disease. "On behalf of the entire Kyverna team, I want to thank Jeff for his expertise and leadership in helping build Kyverna's transformative Treg platform and establishing an outstanding scientific team," added Dr. Borie. Van Blarcom joins Kyverna from Allogene Therapeutics where he most recently served as executive director, head of Protein Engineering and Research Operation; he joined Allogene shortly after the company acquired the allogeneic cell therapy assets from Pfizer. In this role, he contributed to developing the scientific strategy, led cross-functional teams responsible for execution, and oversaw scientific operations. Van Blarcom also built the Protein Engineering Department that is responsible for protein sciences and technology development and led to co-inventorship on more than fifteen of Allogene's pending or issued patents. Prior to Allogene, Van Blarcom held several roles of increasing responsibility at Pfizer and was involved in their initial work on allogeneic CAR T cells that is now part of Allogene. He also spent time at Amgen where he began his industry career. His work has resulted in more than twenty peer-reviewed publications. Van Blarcom received his Ph.D. in chemical engineering from the University of Texas at Austin and a B.S. in chemical engineering from North Carolina State University. "Joining Kyverna is an opportunity to partner with a talented management team and help build an innovative company focused on revolutionizing how we treat serious autoimmune and inflammatory diseases. I am thrilled to apply my experience in cell therapy research toward making new modalities that can potentially cure severe immune-related diseases and change the lives of patients living with autoimmune diseases," said Van Blarcom.

Kyverna Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kyverna Therapeutics Rank

  • When was Kyverna Therapeutics founded?

    Kyverna Therapeutics was founded in 2018.

  • Where is Kyverna Therapeutics's headquarters?

    Kyverna Therapeutics's headquarters is located at 5980 Horton St, Emeryville.

  • What is Kyverna Therapeutics's latest funding round?

    Kyverna Therapeutics's latest funding round is Series B.

  • How much did Kyverna Therapeutics raise?

    Kyverna Therapeutics raised a total of $110M.

  • Who are the investors of Kyverna Therapeutics?

    Investors of Kyverna Therapeutics include Gilead Sciences, Westlake Village BioPartners, Vida Ventures, LYFE Capital, Intellia Therapeutics and 10 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.